window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 7, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Alchemab Therapeutics

  • Advanced Therapies,Digital & Data,Drug Discovery & Development

    Alchemab strikes $415m licensing deal with Lilly for ALS candidate ATLX-1282

    UK-based Alchemab Therapeutics has signed a landmark licensing agreement with [...]

    May 5, 2026
  • Biotech & Pharma Business

    Alchemab Therapeutics signs $415m licensing deal with Lilly for ALS program

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Piramal Pharma reports 22.6% emissions reduction and zero OAI observations in sustainability report
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain, Research & Development
  • FDA approves ViiV’s Tivicay PD for young children with HIV
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Centrix and University of Sussex launch £375,000 data science project for drug development
    Categories: Biotech & Pharma Business, Digital & Data, Drug Discovery & Development, Manufacturing & Supply Chain, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top